Loading clinical trials...
Loading clinical trials...
Precision Medicine Applied to Locally Advanced or Metastatic Poorly Differentiated or Anaplastic Thyroid Cancer Using Tumor Derived Organoids and In-vitro Sensitivity Testing: a Phase 2, Single-center, Open-label, and Non-comparative Study
Conditions
Interventions
Cyclophosphamide+Pemetrexed+5-Fluorouracil
Cyclophosphamide+Doxorubicin+5-Fluorouracil
+8 more
Locations
1
China
West China hospital
Chengdu, Sichuan, China
Start Date
December 1, 2024
Primary Completion Date
December 1, 2025
Completion Date
July 1, 2026
Last Updated
December 3, 2024
NCT06316895
NCT07092514
NCT06524167
NCT07436455
NCT06558981
NCT01660984
Lead Sponsor
West China Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions